Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 68071-2276

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 68071-2276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2276 9)

Atorvastatin Calcium 80 mg film-coated tablets packaging label from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 90 tablets. Manufacturer is Sun Pharmaceutical Industries Limited, Mohali, India. The label includes NDC 68071-2276 with instructions to see the manufacturer's label for full ingredients, storage temperature guidance, and warnings to keep out of reach of children.*

FDA Label Image

Structure (Image 01)

Chemical structure of Atorvastatin Calcium, showing the molecular arrangement including phenyl groups, fluorophenyl ring, hydroxyl groups, and calcium ion coordination with three water molecules as indicated.*

FDA Label Image

Figure1 (Image 02)

A line graph comparing the cumulative incidence (%) over 3.5 years between Atorvastatin and Placebo groups. The solid line represents Atorvastatin and the dashed line represents Placebo, showing lower cumulative incidence in the Atorvastatin group over time.*

FDA Label Image

Figure 2 (Image 03)

A Kaplan-Meier curve showing cumulative hazard (%) over time to first primary endpoint for Atorvastatin versus Placebo groups through four years of follow-up. The graph compares event rates with Atorvastatin demonstrating a lower cumulative hazard than Placebo, with a hazard ratio of 0.63 (95% CI 0.48-0.83) and p=0.001.*

FDA Label Image

Figure 3 (Image 04)

A comparative line graph showing the percentage of subjects experiencing a major cardiovascular event over five years for Atorvastatin 10 mg and Atorvastatin 80 mg. The x-axis represents time in years to the first major cardiovascular endpoint. The y-axis shows the percentage of subjects experiencing the event. Atorvastatin 80 mg demonstrates a lower event rate compared to 10 mg, with a hazard ratio of 0.78 (95% CI 0.69-0.89) and a p-value of 0.0002.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.